Akcea Therapeutics, Inc. Stock News

In a report released today, Chad Messer from Needham reiterated a Buy rating on Geron (GERN – Research Report), with

SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, tod

Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Biogen reports positive data from the NURTURE study. Magenta quits inherited metabolic disorder study. Clovis completes enrolment in RUBRACA study.

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Avita Medical (RCEL – Research Report) today and set a price

AKCA is a highly uninteresting stock - perhaps just the kind we need in these times. It has two approved products and a long pipeline in rare diseases. AKCA is

William Blair analyst Myles Minter reiterated a Buy rating on Neurocrine (NBIX – Research Report) on June 8. The company’s

Needham analyst Chad Messer reiterated a Buy rating on Selecta Biosciences (SELB – Research Report) today and set a price

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN

Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Commonwealth Equity Services LLC increased its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 3.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchang

Acadian Asset Management LLC lessened its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 63.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and